Merck & Company, Inc. (MRK)
Latest news, insights and market data
Market Data
AI Insights
Merck's Keytruda sales growth is expected to slow as it reaches peak penetration, raising concerns about its future revenue. A recent court ruling in the Netherlands has also restricted the sale of subcutaneous Keytruda in several European markets. This could impact Merck's oncology revenue, which is vital to its overall performance. Keep an eye on how these developments affect investor sentiment moving forward.
Latest News
| Title | Published |
|---|---|
How Unusual Is Zoetis's Latest Sales Growth? How Unusual Is Zoetis's Latest Sales Growth? | about 6 hours ago |
Are You Overpaying For Regeneron Stock Versus Its Rivals? Are You Overpaying For Regeneron Stock Versus Its Rivals? | about 12 hours ago |
Merck (MRK) Laps the Stock Market: Here's Why Merck (MRK) Laps the Stock Market: Here's Why | about 13 hours ago |
Is One Older Drug The Biggest Risk To Bristol Myers Squibb Stock? Is One Older Drug The Biggest Risk To Bristol Myers Squibb Stock? | about 13 hours ago |
Why This Pharma Pro Likes Johnson & Johnson, Eli Lilly, and Merck Stock Why This Pharma Pro Likes Johnson & Johnson, Eli Lilly, and Merck Stock | about 16 hours ago |
What Changed In Amgen's Story? What Changed In Amgen's Story? | about 17 hours ago |
Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal | about 19 hours ago |
How Unusual Is Zoetis's Latest Sales Growth?
How Unusual Is Zoetis's Latest Sales Growth?
Are You Overpaying For Regeneron Stock Versus Its Rivals?
Are You Overpaying For Regeneron Stock Versus Its Rivals?
Merck (MRK) Laps the Stock Market: Here's Why
Merck (MRK) Laps the Stock Market: Here's Why
Is One Older Drug The Biggest Risk To Bristol Myers Squibb Stock?
Is One Older Drug The Biggest Risk To Bristol Myers Squibb Stock?
Why This Pharma Pro Likes Johnson & Johnson, Eli Lilly, and Merck Stock
Why This Pharma Pro Likes Johnson & Johnson, Eli Lilly, and Merck Stock
What Changed In Amgen's Story?
What Changed In Amgen's Story?
Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal
Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal